| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2009;119:53-61.)
© 2009 American Heart Association, Inc.
Hypertension |
From the Department of Cardiovascular Sciences, University of Leicester, Leicester, UK (B.W., P.S.L., H.T.); University Department of Medicine, Manchester Royal Infirmary, Manchester, UK (J.K.C.); Barts and the London, Queen Marys School of Medicine, London, UK (D.C.); International Centre for Circulatory Health, Imperial College, London, UK (A.D.H., S.T.); and Beaumont Hospital and Royal College of Surgeons, Dublin, Ireland (A.S.).
Correspondence to Bryan Williams, MD, FRCP, FAHA, Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Building, Leicester Royal Infirmary, Leicester, LE2 7LX, UK. E-mail bw17{at}le.ac.uk
Received April 15, 2008; accepted September 30, 2008.
Background— Statins reduce the risk of cardiovascular events in people with hypertension. This benefit could arise from a beneficial effect of statins on central aortic pressures and hemodynamics. The Conduit Artery Function Evaluation–Lipid-Lowering Arm (CAFE-LLA) study, an Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) substudy, investigated this hypothesis in a prospective placebo-controlled study of treated patients with hypertension.
Methods and Results— CAFE-LLA recruited 891 patients randomized to atorvastatin 10 mg/d or placebo from 5 centers in the United Kingdom and Ireland. Radial artery applanation tonometry and pulse-wave analysis were used to derive central aortic pressures and hemodynamic indices at repeated visits over 3.5 years of follow-up. Atorvastatin lowered low-density lipoprotein cholesterol by 32.4 mg/dL (95% confidence interval [CI], 28.6 to 36.3) and total cholesterol by 35.1 mg/dL (95% confidence interval, 30.9 to 39.4) relative to placebo. Time-averaged brachial blood pressure was similar in CAFE-LLA patients randomized to atorvastatin or placebo (change in brachial systolic blood pressure, –0.1 mm Hg [95% CI, –1.8 to 1.6], P=0.9; change in brachial pulse pressure, –0.02 mm Hg [95% CI, –1.6 to 1.6], P=0.9). Atorvastatin did not influence central aortic pressures (change in aortic systolic blood pressure, –0.5 mm Hg [95% CI, –2.3 to 1.2], P=0.5; change in aortic pulse pressure, –0.4 mm Hg [95% CI, –1.9 to 1.0], P=0.6) and had no influence on augmentation index (change in augmentation index, –0.4%; 95% CI, –1.7 to 0.8; P=0.5) or heart rate (change in heart rate, 0.25 bpm; 95% CI, –1.3 to 1.8; P=0.7) compared with placebo. The effect of statin or placebo therapy was not modified by the blood pressure–lowering treatment strategy in the factorial design.
Conclusions— Statin therapy sufficient to significantly reduce cardiovascular events in treated hypertensive patients in ASCOT did not influence central aortic blood pressure or hemodynamics in a large representative cohort of ASCOT patients in CAFE-LLA.
Related Article:
This article has been cited by other articles:
![]() |
J. D. Cameron Wave Intensity Analysis and Central Blood Pressure Hypertension, November 1, 2009; 54(5): 958 - 959. [Full Text] [PDF] |
||||
![]() |
C. Manisty, J. Mayet, R. J. Tapp, P. S. Sever, N. Poulter, S. A. McG. Thom, A. D. Hughes, and on behalf of the ASCOT Investigators Atorvastatin Treatment Is Associated With Less Augmentation of the Carotid Pressure Waveform in Hypertension: A Substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT) Hypertension, November 1, 2009; 54(5): 1009 - 1013. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Orr, A. L. Dengo, J. M. Rivero, and K. P. Davy Arterial Destiffening With Atorvastatin in Overweight and Obese Middle-Aged and Older Adults Hypertension, October 1, 2009; 54(4): 763 - 768. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Avolio, L. M. Van Bortel, P. Boutouyrie, J. R. Cockcroft, C. M. McEniery, A. D. Protogerou, M. J. Roman, M. E. Safar, P. Segers, and H. Smulyan Role of Pulse Pressure Amplification in Arterial Hypertension: Experts' Opinion and Review of the Data Hypertension, August 1, 2009; 54(2): 375 - 383. [Full Text] [PDF] |
||||
![]() |
K. K. Koh Combination Treatment to Prevent Atherosclerosis Hypertension, July 1, 2009; 54(1): e10 - e10. [Full Text] [PDF] |
||||
![]() |
T. Kushiro Response to Combination Treatment to Prevent Atherosclerosis Hypertension, July 1, 2009; 54(1): e11 - e11. [Full Text] [PDF] |
||||
![]() |
J. K. Cruickshank, M. Rezailashkajani, and G. Goudot Arterial Stiffness, Fatness, and Physical Fitness: Ready for Intervention in Childhood and Across the Life Course? Hypertension, April 1, 2009; 53(4): 602 - 604. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |